LL-37 (Cathelicidin) vs PEG-MGF

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

LL-37 (Cathelicidin)

LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.

Full details →

PEG-MGF

PEG-MGF (PEGylated Mechano Growth Factor) is a variant of IGF-1 that is produced in response to muscle damage. PEGylation extends its half-life from minutes to several hours, making it practical for use.

Full details →

Side-by-Side Comparison

AspectLL-37 (Cathelicidin)PEG-MGF
MechanismDisrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects.Activates muscle satellite cells (stem cells) and promotes their fusion to existing muscle fibers for repair and growth. MGF is produced naturally in response to mechanical stress on muscles.
Typical DosageResearch protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections.Research protocols typically use 200-400mcg injected into targeted muscle groups 2-3 times weekly, usually post-workout.
AdministrationSubcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols.Intramuscular injection, ideally into muscles trained that day. Best administered post-workout when satellite cell activation is relevant.
Side EffectsInjection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses.Injection site soreness, potential hypoglycemia, and localized swelling. Generally well-tolerated.
Best For

What They Have in Common

Both LL-37 (Cathelicidin) and PEG-MGF are commonly used for:

Key Differences

Unique to LL-37 (Cathelicidin):

Unique to PEG-MGF:

Ready to Learn More?